Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 96, Issue 1, Pages 47-57
Publisher
Springer Nature
Online
2012-05-19
DOI
10.1007/s12185-012-1093-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system
- (2010) Tetsuzo Tauchi et al. LEUKEMIA RESEARCH
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy
- (2009) Hyun-Gyung Goh et al. LEUKEMIA & LYMPHOMA
- Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations
- (2009) Dongho Kim et al. LEUKEMIA RESEARCH
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- (2008) T. P. Hughes et al. BLOOD
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- (2008) D. Marin et al. BLOOD
- Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- (2008) S. Branford et al. BLOOD
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia
- (2007) Hagop Kantarjian et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now